OSLI Retina

July 2019

Issue link: http://osliretina.healio.com/i/1142233

Contents of this Issue

Navigation

Page 65 of 67

468 Ophthalmic Surgery, Lasers & Imaging Retina | Healio.com/OSLIRetina 6900 Grove Road Thorofare, NJ 08086-9447 Phone: 856-848-1000 Email: osli@healio.com Healio.com/OSLIRetina SLACK I N C O R P O R A T E D ® Follow OSLIJournal OSLI Retina SLACK Incorporated News and Notes SLACK Incorporated Chief Content Officer Joan-Marie Stiglich, ELS EDITORIAL Senior Editorial Director David W. Mullin Executive Editor Cara Dickinson SALES Chief Commercial Officer Matthew J. Holland Group Sales Director, Eye Care Scott Wright National Account Manager Laura Renna Director, Sales Administration and Support Carolyn Boerner Recruitment/Classified Sales Representative Bernadette Hamilton Sales Coordinator, Recruitment Jennifer Carroll Reprints/Eprints Licensing Opportunities: Sheridan Content Solutions scsreprints@sheridan.com DESIGN Creative Director Thomas Cavallaro Production and Circulation Director Cheryl McKeown Production Associate Ryan Davis The Wyanoke Group President Peter N. Slack Chief Operating Officer John C. Carter Chief Financial Officer Darrell Blood Senior Vice President Denise Mealey Chief Technology Officer Linda Baker News and Notes Alimera's Iluvien Receives Positive Funding Recommendation The U.K.'s National Institute of Health and Care Excellence has recommended funding for Iluvien (Alimera Sciences, Alpharetta, GA) as treatment for noninfec- tious posterior uveitis, Alimera announced. With this recommendation, the U.K.'s National Health Service will pay for prescriptions for the fluocinolone acetonide intravitreal implant 0.19 mg treat- ment of noninfectious uveitis affecting the posterior segment, according to the company press release. Iluvien is also indicated for and funded for the treatment of diabetic macular edema in the U.K. "We continue to execute on our plans to launch Iluvien's new indication in Europe for noninfectious posterior uveitis, a significant and, we believe, poorly served medical need. The positive funding recommendation from NICE facili- tates patient access in England and Wales for this second indication with funding from the NHS," said Rick Eiswirth, president and CEO of Alimera Sciences. The Iluvien sustained release implant is designed to release submicrogram levels of fluocinolone acetonide for 36 months. Originally published on www.Healio.com on June 20, 2019. Ophthalmic Surgery, Lasers & Imaging Retina® (ISSN-2325-8160, Canadian BN-12978 0466 RT ) is published 12 times per year by SLACK Incorporated®, and is an official publication of ARVO/ISIE. Publication Office: SLACK Incorporated®, 6900 Grove Road, Thorofare, NJ 08086-9447. Telephone (856) 848-1000. Printed in the USA. Periodicals Class Postage Paid at Deptford, NJ 08096 and at additional mailing offices. Contents copyrighted by SLACK Incorporated®, 2019. All rights reserved. No part of this publication may be reproduced with- out prior written consent of the publisher. All requests to reprint or use material published herein should be directed to the Request Permissions link on every article page at Healio.com/ophthalmology/journals/osli. Subscription rates in the U.S. and possessions: Individuals: One year—print $222, electronic only: $197. Institutional: One year—$692. Residents and fellows: $111 for one year (a letter of certification indicating residency of the subscriber is required). Canada add 5% GST, all other countries add $71 per year. All subscriptions, without exception, will start with the first issue pub- lished after the order is received. Single copies and back issues, when available, are $99. Payment must accompany order. Subscrip- tion requests should be addressed to the publisher. Change of Address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new ad- dresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Duplicate copies will not be sent to re- place ones undelivered through failure to notify the publisher of change of address. POSTMASTER: Send Form 3547 to Ophthalmic Surgery, Lasers & Imaging Retina®, SLACK Incorporated®, 6900 Grove Road, Thorofare, NJ 08086-9447. Articles are intended for informational purposes only and should not be used as the basis of patient treatment. All opinions expressed by authors and quoted sources are their own and do not necessarily reflect the opinions of the editors, publisher, or editorial boards of SLACK Incorporated®. The acceptance of advertising in no way implies endorsement by the editors, publisher, or editorial boards of SLACK Incorporated®. See website for print and web advertising policy. Readers with queries about the Journal's policies on error correction, version control, journal of record, ancillary material, or archiving should contact osli@healio.com. The Journal staff have no financial relationships to disclose. Financial disclosures for the Editor and members of the Editorial Board are on file with the editorial office. Indexed in: Medline/PubMed, ProQuest, EMCare, EMBASE, Science Citation Index, Current Contents/Clinical Medicine, BioEn- gineering Abstracts, CAB Abstracts, and SCOPUS.

Articles in this issue

Links on this page

Archives of this issue

view archives of OSLI Retina - July 2019